Onconetix Secures $12.9 Million in Financing via Series D Preferred Stock and Warrants, Ends Merger Agreement with Ocuvex, Inc., and Settles $8.8 Million Debt with Veru, Inc.
Financing Transaction Details: Onconetix, Inc. completed a private placement on September 22, 2025, raising approximately $12.9 million through the sale of Series D Convertible Preferred Stock and warrants, with a portion of the proceeds used to pay off debt to Veru, Inc.
Use of Proceeds: The company plans to utilize the remaining funds for costs related to terminating a previous business combination with Ocuvex, Inc., as well as for working capital and general corporate purposes.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on ONCO
About ONCO
About the author
Authparency.ai Wins First Prize at Southlake Innovation Cup for Solving Healthcare Authorization Issues
- Award Recognition: Authparency.ai's first prize at the Southlake Innovation Cup highlights its unique approach to addressing the $31 billion annual administrative burden in the U.S. healthcare system, enhancing its market position and attracting increased attention.
- Operational Efficiency Improvement: The platform significantly streamlines the prior authorization process by combining deep operational expertise with AI, reducing patient care delays and denials, thereby enhancing workflow efficiency for healthcare providers.
- Market Expansion Plans: Authparency.ai aims to leverage the momentum from the Innovation Cup to accelerate deployment across hospital systems and deepen payer-specific intelligence through expanded transaction volume, with plans to formalize strategic partnerships with EHR vendors and healthcare networks throughout 2026.
- Growing Industry Demand: This award marks a significant milestone, underscoring the increasing demand for practical, operationally informed AI solutions in healthcare, further validating the sustainability and market potential of its business model.
Onconetix Secures $12.9 Million in Financing via Series D Preferred Stock and Warrants, Ends Merger Agreement with Ocuvex, Inc., and Settles $8.8 Million Debt with Veru, Inc.
Financing Transaction Details: Onconetix, Inc. completed a private placement on September 22, 2025, raising approximately $12.9 million through the sale of Series D Convertible Preferred Stock and warrants, with a portion of the proceeds used to pay off debt to Veru, Inc.
Use of Proceeds: The company plans to utilize the remaining funds for costs related to terminating a previous business combination with Ocuvex, Inc., as well as for working capital and general corporate purposes.
